Marco Pappagallo

Neurology

11 Overlook Rd Ste B110
Summit, NJ 07901

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Depression severity and efficacy outcomes: post hoc analyses from a phase 3 trial of esmethadone for the adjunctive treatment of major depressive disorder with inadequate response to standard antidepressants.

Depression severity and efficacy outcomes: post hoc analyses from a phase 3 trial of esmethadone for the adjunctive treatment of major depressive disorder with inadequate response to standard antidepressants.

Journal: International clinical psychopharmacology

Published: February 27, 2026

Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms.

Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms.

Journal: Pharmacological research

Published: October 30, 2025

Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Antidepressant Tachyphylaxis: An Exploratory Post Hoc Analysis From a Phase 3 Randomized Controlled Trial.

Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Antidepressant Tachyphylaxis: An Exploratory Post Hoc Analysis From a Phase 3 Randomized Controlled Trial.

Journal: The Journal of clinical psychiatry

Published: October 08, 2025

Reasons for Maintaining the Classification of Esmethadone as an Investigational Uncompetitive NMDAR Antagonist Rapid Antidepressant: Reply to Ferré and Michaelides.

Reasons for Maintaining the Classification of Esmethadone as an Investigational Uncompetitive NMDAR Antagonist Rapid Antidepressant: Reply to Ferré and Michaelides.

Journal: The Journal of clinical psychiatry

Published: September 18, 2025

Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label Study.

Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label Study.

Journal: The Journal of clinical psychiatry

Published: February 25, 2025

A novel artificial intelligence-based methodology to predict non-specific response to treatment.

A novel artificial intelligence-based methodology to predict non-specific response to treatment.

Journal: Psychiatry research

Published: December 09, 2024

N-methyl-D-aspartate Receptors and Depression: Linking Psychopharmacology, Pathology and Physiology in a Unifying Hypothesis for the Epigenetic Code of Neural Plasticity.

N-methyl-D-aspartate Receptors and Depression: Linking Psychopharmacology, Pathology and Physiology in a Unifying Hypothesis for the Epigenetic Code of Neural Plasticity.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: October 07, 2024

Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial.

Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial.

Journal: The Journal of clinical psychiatry

Published: June 25, 2024

Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment.

Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment.

Journal: Drugs in R&D

Published: June 23, 2024

Effect of Time From Onset of Major Depressive Disorder on the Therapeutic Response to Esmethadone (REL-1017).

Effect of Time From Onset of Major Depressive Disorder on the Therapeutic Response to Esmethadone (REL-1017).

Journal: The Journal of clinical psychiatry

Published: May 20, 2024

Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone'.

Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone'.

Journal: Molecular psychiatry

Published: January 16, 2024

Drug-Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism.

Drug-Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism.

Journal: Drugs in R&D

Published: November 02, 2023

Showing 1-12 of 37

Last Updated: 09/26/2026